Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
Renal anemia is an important clinical manifestation of chronic kidney disease.The relative or absolute deficiency of erythropoietin(EPO) is the main cause of renal anemia.At present,renal anemia is treated mainly with EPO analogues combined with ferralia.However,its clinical application is limited d...
Saved in:
| Main Authors: | TU Yan, ZHANG Xiao-liang |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2020-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57906601&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01) -
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01) -
Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01) -
Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on hemoglobin, B-type natriuretic peptide, and renal function in anemic heart failure patients: A systematic review and meta-analysis
by: Hidekatsu Fukuta, et al.
Published: (2025-06-01) -
Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01)